MAY 26·SEC EDGARLow
Champoux Jennifer sold $41K of GLUE
Champoux Jennifer (Chief Operating Officer) sold 2,176 shares of Monte Rosa Therapeutics, Inc. (GLUE) at $19.00 on 2026-05-22 under a Rule 10b5-1 trading plan.
StockHealthcare · Biotechnology
$GLUE
Monte Rosa Therapeutics, Inc.
Price · $GLUEvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 0
- Neutral
- 1
- Bearish
- 0
Top stories · $GLUEMore →
MAY 20·The Manila Times
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) announced its management will participate in two upcoming investor conferences: the TD Cowen 7th Annual Oncology Innovation Summit and the Jefferies Global Healthcare Conference. The company specializes in developing novel molecular glue degrader (MGD)-based medicines, utilizing its QuEEN™ discovery engine. Webcasts of the fireside chats will be available on Monte Rosa's investor relations website.
APR 16·Stock Titan
[Form 4] Monte Rosa Therapeutics, Inc. Insider Trading Activity
Monte Rosa Therapeutics President & CEO Markus Warmuth reported an open-market sale of 8,000 shares of Common Stock on April 14, 2026, at a weighted average price of $17.6406 per share. Following this transaction, Warmuth directly holds 605,471 shares, maintaining a substantial equity position in the company. This insider trading activity is categorized with a "High" impact and "Negative" sentiment.